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Original Article
Triptan overuse in the Dutch general
population: A nationwide
pharmaco-epidemiology database
analysis in 6.7 million people
F Dekker1, NJ Wiendels1, V de Valk2, C van der Vliet2,
A Knuistingh Neven1, WJJ Assendelft1 and MD Ferrari1
Abstract
Introduction: A population-based observational study was used to assess the prevalence, demographics, risk factors, and
costs of triptan overuse, defined as more than 30 (International Headache Society criteria) or 54 (stringent criteria)
defined daily doses per 3 months.
Methods: Analysis of the Dutch Health Care Insurance Board Database for 2005, which included prescriptions for 6.7
million people (46% of the total Dutch population).
Results: Triptans were used by 85,172 (1.3%) people; of these, 8,844 (10.4%; 95% CI 10.2–10.6) were overusers by
International Headache Society and 2,787 (3.3%; 95% CI 3.2–3.4) were overusers by stringent criteria. The triptan-
specific odds ratios for the rate of International Headache Society overuse compared with sumatriptan were: 0.26 (95%
CI 0.19–0.36) for frovatriptan; 0.34 (95% CI 0.32–0.37) for rizatriptan; 0.76 95% CI 0.68–0.85) for naratriptan; 0.86 (95%
CI 0.72–1.02) for eletriptan; 0.97 (95% CI 0.88–1.06) for zolmitriptan; and 1.49 (95% CI 1.31–1.72) for almotriptan.
Costs for overuse were 29.7 million euros; for the International Headache Society criteria this was 46% of total costs and
for stringent criteria it was 23%.
Discussion: In the Dutch general population, 1.3% used a triptan in 2005, of which 10.3% were overusers and accounted
for half of the total costs of triptans. Users of frovatriptan, rizatriptan and naratriptan had a lower level of overuse.
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Introduction
Migraine is a common (1,2), highly disabling (3,4), and
costly (5) episodic brain disorder (6). Attacks typically
last 1–2 days and strike with a median frequency of 1.5
per month; 10% of patients have two or more attacks
per week (6). A high attack frequency is associated with
a substantial increase of disability (4,7,8), costs (5,9),
and risk of ischemic brain lesions (10,11). Overuse of
acute headache agents is increasingly recognized as a
paradoxical but major reason for sometimes dramatic
increases in the attack frequency (medication-overuse
headache) (7,12–15). Medication-overuse headache
is increasingly recognized as a problem worldwide,
with an estimated prevalence in the general population
of 1–4% (12,14).
Triptans, selective 5-HT1B/1D (serotonin) receptor
agonists, are specific, effective, and well tolerated
agents to treat migraine attacks (16–18). Regular use
of a triptan on ten or more days a month for more than
three consecutive months may cause triptan overuse
headache (13). Studies in headache clinics and open
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populations suggest an average critical dosage of 18
single doses per month (19,20). With the increasing
availability of triptans over the counter and the cur-
rently often advocated (21) but still unproven instruc-
tion to treat attacks as early as possible while the
headache is still mild, the prevalence of triptan overuse
headache is likely to increase. This might have a major
impact on the quality of life of migraine patients (22,23)
and will cause a considerable increase in costs (9).
Overuse of triptans does not suddenly emerge; it
starts with increasing use, develops in to more use,
even more use and then sometimes results in overuse.
To describe this phenomenon these different levels of
triptan use are relevant, starting from a lower threshold
of triptan overuse (overuse or seriously at risk of over-
use, which may give an overestimation) up to a strict
threshold (which may result in underestimation). To
this end, we had access to a unique database of the
national Dutch Health Care Insurance Board, which
monitors, at the individual level, the dispensation of
prescribed drugs at pharmacies for all inhabitants of
the Netherlands.
In the present study, we sought to assess: (i) the
prevalence and associated costs of triptan overuse in
the Dutch general population; (ii) the demographic
characteristics of triptan overusers to identify possible
risk factors; and (iii) whether the level of overuse differs
among the seven available triptans.
Methods
Study setting
Data were obtained from the Drug Information Project
(GIP database) of the Health Care Insurance Board
(CVZ). The CVZ is a public authority in the domain
of drugs. As an independent non-profit governing
body, it monitors conditions of the health insurance
scheme in the Netherlands. In 2005, more than 10 mil-
lion people (65% of all inhabitants of the Netherlands)
were mandatorily insured as a result of the Sickness
Fund Act. People were eligible for sickness fund insur-
ance if they had a yearly income of less than E33,000.
The GIP database registered the prescribed drugs that
were dispensed at pharmacies for patients that are
insured by sickness funds. All prescription drugs are
coded according to the Anatomical, Therapeutic and
Chemical (ATC) classification (24). Each registered
patient has an anonymous unique identification
number, which allows complete observation of medica-
tion use over time per patient. Each prescription also
includes information on what insurance companies pay
to the pharmacist, allowing an exact calculation of the
costs. For migraine patients in the Netherlands, there
were no financial restrictions in using acute or
prophylactic headache therapy in the study year 2005
as long as a physician prescribed the medication. In the
Netherlands over-the-counter sales of triptans is
prohibited.
Definitions
A triptan user was defined as a patient for whom at
least one prescribed triptan was dispensed in 2005.
We used two definitions for triptan overuse, one
based on the criteria of The International Headache
Society (IHS), that is, use of a triptan on more than
10 days a month for 3 months (13), and a second
more stringent definition, based on studies in headache
clinics, that is, use of 18 single doses or more per month
for 3 consecutive months (19). When patients use 18
defined daily doses (DDDs) or more over a long period,
chronic daily headache based on medication overuse is
evident (19).
We converted these criteria into DDD per year,
which is, according to the World Health Organization
(WHO), the standardized dosage per day of a drug
when prescribed for the registered indication (Table 1)
(24). The DDD system has been used in previous trip-
tan database studies and is the system of choice when
comparing drugs (http://www.whocc.no/) (25)
Accordingly, ‘IHS triptan overuse’ was defined as use
of 120 DDDs or more per year and ‘stringent triptan
overuse’ as use of 216 DDDs or more per year. As use
and overuse of triptans may fluctuate considerably ((12)
and see Results), and because our aim was to identify
consistent rather than incidental overuse, we calculated
the 3 month use using the average triptan consumption
over a 12 month period rather than over a 3 month
period only. For calculating the DDDs we had the
real number of tablets (and other formulations) at
our disposal.
Use of migraine prophylactic medication was
defined as the dispensation of at least one prescription
in 2005 of any medication that is registered in the
Netherlands for migraine prophylaxis. Most migraine
prophylactic agents have multiple disease indications.
As the indication for a prescription is not recorded in
the database, we could not establish whether the med-
ication was prescribed for migraine or another disorder.
Statistical analysis
Data are summarized as means with 95% confidence
intervals (95% CIs) for continuous variables and as
numbers and percentages of subjects for categorical
variables. Differences between groups are presented
with 95% CIs. For differences among the triptans for
the rate of overuse, we calculated the odds ratios (OR)
with 95% CIs using sumatriptan as the reference.
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As sumatriptan is the longest available and most widely
prescribed triptan, we adjusted the OR for duration of
availability, by the method of indirect standardization.
For this duration we took the number of years the drug
was on the market without any surcharge (correspond-
ing to the start of substantial use in the Netherlands).
For statistical analyses we used SAS Enterprise Guide
version 4.1.
Results
We found that 10% of all triptan users, which is 0.1%
of the total Dutch general population, were overusing
triptans. They were responsible for nearly half of the
total costs for triptans.
We could assess the medication use of 6.7 million
people, covering approximately 46% of the total
Dutch population and 67% of all people that were
insured with the sickness fund. The remaining part of
the population could not be included in this study
because of reasons unlikely to have introduced bias,
such as non-connectable databases and other means
of health insurance.
In 2005, 85,172 people (1.3% of the total sample)
had received at least one prescription for a triptan. Of
these 31,841 (37.4%) had received only one prescription
and 5,536 (6.5%) had received prescriptions for more
than one triptan. The vast majority of prescriptions
(95%) were from general practitioners; only 5% were
from neurologists or other specialists. Table 2 compares
the characteristics of triptan users to those of the total
population. The majority of triptan users were female
and over 30 years of age. Nineteen percent of triptan
users also took medication indicated for migraine
prophylaxis.
Numbers and characteristics of overusers versus
non-overusers are presented in Table 3. Among the
85,172 triptan users, 8,844 people were overusers
according to the IHS criteria (10.4%; 95% CI: 10.2–
10.6), and 2787 people according to the stringent crite-
ria (3.3%; 3.2–3.4). IHS triptan overusers accounted
for 47.3% (47.2–47.3) and stringent overusers for
23.0% (20.0–24.1) of the total use of triptans.
Overusers were equally distributed among females
and males and across the whole life span, although on
average they were older than non-overusers: 60% of
overusers were in the fifth and sixth decade of life.
Prophylactic medication was more frequently dispensed
in overusers, 30.4% of IHS and 32.1% of stringent
overusers, than in non-overusers (17.9%).
Sumatriptan is available in four different formula-
tions and two oral doses. The vast majority used just
one formulation, although overusers (IHS: 17.2%;
stringent: 24%) more often used multiple formulations
than did non-overusers (5.8%). The majority exclu-
sively used tablets: 64.2% of the total sample; 62.4%
of the non-overusers; 75.4% of the IHS overusers; and
74.1% of the stringent overusers. Subcutaneous injec-
tions were used by 10.3% of the non-overusers, 6.6% of
the IHS overusers and 4.6% of the stringent overusers.
Table 4 shows the numbers and proportions of
patients in each of the three categories: all users of a
triptan, triptan non-overusers and triptan overusers.
The majority of patients used only one triptan.
Sumatriptan was by far the most frequently prescribed
Table 1. Defined daily dose per triptan according to the World Health Organization (22)
Triptan Year of introduction Formulation Defined daily dose (DDD)
Sumatriptan 1991 (1996*) 50 mg tablet 1 tablet
100 mg tablet ½ tablet
25 mg suppository 1 supp
20 mg nasal spray 1 spray
6 mg subcutaneous injection 1 injection
Naratriptan 1997 2.5 mg tablet 1 tablet
Zolmitriptan 1997 2.5 mg tablet 1 tablet
Rizatriptan 1998 5 mg tablet 2 tablets
10 mg tablet 1 tablet
Eletriptan 2000 20 mg tablet 2 tablets
40 mg tablet 1 tablet
Almotriptan 2000 12.5 mg tablet 1 tablet
Frovatriptan 2001 2.5 mg tablet 1 tablet
*First year of full availability of tablets without any surcharge.
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triptan in all three categories. Overuse was observed for
all triptans, but the level of overuse differed signifi-
cantly per triptan, as presented in Table 5. Compared
with sumatriptan, the odds ratio (OR) for the rate of
IHS overuse was 0.11 (95% CI 0.08–017) for frovatrip-
tan, 0.27 (95% CI 0.25–0.28) for rizatriptan, 0.48 (95%
CI 0.40–0.57) for almotriptan, 0.68 (95% CI 0.62–0.74)
for naratriptan, 0.83 (95% CI 0.72–0.95) for eletriptan
and 0.86 (95% CI 0.80–0.93) for zolmitriptan. When
adjusted for the different durations of availability, the
level of overuse remained significantly reduced for fro-
vatriptan (0.26; 95% CI 0.19–0.36), rizatriptan (0.34;
95% CI 0.32–0.37) and naratriptan (0.76; 95% CI
0.68–0.85), but not for eletriptan (0.86; 95% CI 0.72–
1.02), zolmitriptan (0.97; 95% CI 0.88–1.06) and almo-
triptan (1.49; 95% CI 1.31–1.72). Similar profiles were
seen for stringent overusers. It should be noted that the
absolute numbers of users and overusers for naratrip-
tan and especially frovatriptan are very small, and that
the duration of availability of especially frovatriptan
was very short. These factors might have biased the
results for these triptans (see Discussion). The overuse
in the group of patients using more than one triptan is
twice as high as that in the group using just one triptan.
The crude ORs for overuse compared with sumatriptan
(1.00) are 2.01 (95% CI 1.87–2.16) for the IHS criteria
and 2.12 (95% CI 1.98–2.37) for the stringent criteria.
In the group of patients using more than one triptan, it
is not possible to calculate the adjusted odds because of
the differences between duration on the market of the
different triptans.
The costs of triptan use and overuse are shown in
Figures 1 and 2. Total costs of triptan use in 2005 were
E29.7 million, E349 per triptan user and E4.43 per
Table 2. Clinical characteristics and demographics of triptan users compared with the total population
Total population Triptan users
N¼ 6,704,627 N¼ 85,172
n (%) n (%)
Females 3,665,773 (55) 71,047 (83)
Age <20 685,352 (19) 1916 (3)
20–29 459,630 (13) 9616 (14)
30–39 586,641 (16) 16,620 (23)
40–49 588,504 (16) 21,628 (30)
50–59 503,518 (14) 14,615 (21)
60–69 365,634 (10) 4926 (7)
>70 476,494 (13) 1726 (2)
Males 3,038,854 (45) 14,125 (17)
Age <20 719,131 (24) 871 (6)
20–29 447,465 (15) 1782 (13)
30–39 486,320 (16) 3499 (25)
40–49 433,975 (14) 3644 (26)
50–59 371,537 (12) 2725 (19)
60–69 297,714 (10) 1194 (9)
>70 282,712 (9) 410 (3)
Prophylactic medication* 437,354 (6.5) 16,327 19.2
Propranolol 54,254 (0.8) 6267 (7.4)
Metoprolol 339,244 (5.1) 6985 (8.2)
Pizotiphen 4028 (0.1) 1400 (1.6)
Flunarizine 2803 (0.0) 218 (0.3)
Valproic acid 30,228 (0.5) 1713 (2.0)
Clonidine 13,363 (0.2) 747 (0.9)
Topiramate 3325 (0.0) 1084 (1.3)
*Medication that can be prescribed as prophylactic therapy for migraine. Amitriptyline is not registered and not prescribed as
migraine prophylaxis in the Netherlands.
Methysergide can only be prescribed for a short period to prevent adverse events and was therefore excluded. Source: GIP
database/Health Care Insurance Board.
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N¼ 85,172 N¼ 76,328 N¼ 8844 (95% CI) N¼ 2787 (95% CI)
Female, n (%) 71,047 (83) 63,622 (83) 7,425 (84) 1% (0.2 to 1.4) 2294 (82) 1% (2.5 to 0.4)
Mean age, y (SD) 43 (13) 42 (13) 47 (11) 5 yrs (4.7 to 5.3) 48 (11) 6 yrs (5.2 to 6.2)
Age, n (%)
 20 2787 (3) 2765 (4) 22 (0) 3% (3.5 to 3.2) 6 (0) 3% (3.6 to 3.1)
20–29 11,398 (13) 10,913 (14) 485 (6) 9% (9.3 to 8.3) 113 (4) 10% (11.0 to 9.4)
30–39 20,119 (24) 18,439 (24) 1680 (19) 5% (6.0 to 4.3) 515 (19) 6% (7.1 to 4.2)
40–49 25,272 (30) 22,275 (29) 2997 (34) 5% (3.7–5.7) 964 (35) 5% (3.6–7.2)
50–59 17,340 (20) 14,861 (20) 2479 (28) 9% (7.6–9.5) 789 (28) 9% (7.2–10.6)
60–69 6120 (7) 5210 (7) 910 (10) 4% (2.8–4.1) 298 (11) 4% (2.8–5.1)
70 2136 (2) 1865 (2) 271 (3) 1% (0.3–1.0) 102 (4) 1% (0.6–2.0)
Prophylaxis, n (%)y
Propranolol 6267 (7.4) 5287 (6.9) 980 (11.1) 4% (3.5–4.8) 326 (11.7) 5% (3.6–6.0)
Metoprolol 6985 (8.2) 5868 (7.7) 1,117 (12.6) 5% (4.2–5.7) 352 (12.6) 5% (3.7–6.2)
Pizotifeen 1400 (1.6) 1133 (1.5) 267 (3.0) 2% (1.2–1.9) 106 (3.8) 2% (1.7–3.1)
Flunarizine 218 (0.3) 165 (0.2) 53 (0.6) 0% (0.2–0.6) 17 (0.6) 0% (0.2–0.8)
Valproic acid 1713 (2.0) 1352 (1.8) 361 (4.1) 2% (1.9–2.8) 123 (4.4) 3% (1.9–3.5)
Clonidine 747 (0.9) 628 (0.8) 119 (1.3) 1% (0.3–0.8) 38 (1.4) 1% (0.2–1.0)
Topiramate 1084 (1.3) 757 (1.0) 327 (3.7) 3% (2.3–3.1) 130 (4.7) 4% (2.9–4.5)
Any of the above 16,327 (19.2) 13,635 (17.9) 2692 (30.4) 13% (11.6–13.6) 895 (32.1) 14% (12.5–16.0)
*Stringent overusers are a subgroup of IHS overusers.
yMedication that can be prescribed as prophylactic medication for migraine, but may have been prescribed for other co-morbid disorders.
Source: GIP Database/Health Care Insurance Board.







N¼ 85,172 N¼ 76,328 N¼ 8844 N¼ 2787
n (%) n (%) n (%) n (%)
Single triptan use 79,636 (94) 71,837 (94) 7799 (88) 2416 (87)
Sumatriptan 41,352 (52) 35,798 (50) 5554 (71) 1952 (81)
Naratriptan 3798 (5) 3437 (5) 361 (5) 86 (4)
Zolmitriptan 4983 (6) 4397 (6) 586 (8) 134 (6)
Rizatriptan 25,796 (32) 24,770 (35) 1026 (13) 182 (8)
Eletriptan 1455 (2) 1289 (2) 166 (2) 37 (2)
Almotriptan 1295 (2) 1206 (2) 89 (1) 23 (1)
Frovatriptan 957 (1) 940 (1) 17 (0.2) 2 (0.1)
Multiple triptans 5536 (6) 4491 (6) 1045 (12) 371 (13)
Values are numbers (%) of subjects.
*Stringent overusers are a subgroup of IHS overusers.
Source: GIP Database/Health Care Insurance Board.
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inhabitant. Patients overusing triptans accounted for
46% (IHS criteria) and 23% (stringent criteria) of the
total costs, E1543 per IHS overuser and E2468 per
stringent overuser.
Discussion
We analysed the use and overuse for all seven available
triptans in the Dutch general population in the
year 2005. We could make use of a unique national
Health Care Insurance Board Database, which covered
the medication use of 6.7 million people. Of these, 1.3%
had used a triptan at least once in 2005 and 0.13%
(10.4% of all triptan users) were overusing triptans.
Overusers accounted for almost half of the total
costs for triptans. Remarkably, the level of overuse dif-
fered significantly per triptan. Users of rizatriptan, and
possibly of frovatriptan and naratriptan, showed




>30 DDD/qtr Odds (95%CI)
Stringent criteria*
>54 DDD/qtr Odds (95%CI)
N¼ 85,172 n (%) n (%) Adjusted oddsy n (%) Adjusted oddsy
Sumatriptan 41,352 35,798 (87) 5554 (13) 1.00 (ref) 1952 (5) 1.00 (ref)
Naratriptan 3798 3437 (91) 361 (10) 0.76 (0.68–0.85) 86 (2) 0.52 0.42–0.64
Zolmitriptan 4,983 4397 (88) 586 (12) 0.97 (0.88–1.06) 134 (3) 0.63 0.53–0.75
Rizatriptan 25,796 24,770 (96) 1026 (4) 0.34 (0.32–0.37) 182 (1) 0.17 0.15–0.20
Eletriptan 1295 1206 (93) 89 (7) 0.86 (0.72–1.02) 23 (2) 0.63 0.45–0.86
Almotriptan 1455 1289 (89) 166 (11) 1.49 (1.31–1.72) 37 (3) 0.95 0.73–1.22
Frovatriptan 957 940 (98) 17 (2) 0.26 (0.19–0.36) 2 (0) 0.08 0.03–0.22
>1 triptan§ 5536 4491 (81) 1045 (19) -# -# 371 (7) -# -#
Values are numbers (%).
*Stringent overusers are a subgroup of IHS overusers.
yAdjusted odds for duration of availability of the drug, by method of indirect standardization.
§When using more than one triptan, the adjusted odds cannot be calculated (#) because of the variation in the duration of the availability of the triptan.
Source: GIP Database/Health Care Insurance Board.













Figure 2. The proportion of patients with and without triptan
overuse according to stringent criteria, with the associated cost
and drug use. Percentage of patients with stringent overuse,
generated cost and DDDs (daily defined dose). The top part of
each bar indicates the stringent overusers (54 DDDs/qtr) and
the bottom indicates the non-overusers. Source: GIP Database/
Health Care Insurance Board.













Figure 1. The proportion of patients with and without triptan
overuse according to IHS criteria, with the associated cost and
drug use. Percentage of patients with IHS overuse, generated
cost and DDDs (daily defined dose). The top part of each bar
indicates the IHS overusers (30 DDDs/qtr) and the bottom
indicates the non-overusers. Source: GIP Database/Health Care
Insurance Board.
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substantially lower levels of overuse. When patients use
more than one triptan, the level of overuse is additional
high: a doubling of levels of overuse compared with
when the patient is only using one kind of triptan.
The results of the present study appear robust and
representative because of the large number of patients
included. We used an independent and unbiased
nationwide database with an accurate count of
actual dispense of triptans at pharmacies, covering
nearly half of the total population of the
Netherlands. A potential limitation is that we could
not measure the actual use of triptans by patients. It
seems, however, very unlikely that with an average
use of 210 DDDs in IHS overusers and of 420
DDDs in stringent overusers, many patients would
not have used the dispensed medication.
With regard to these thresholds we can argue that
overuse lies somewhere in between the two presented
thresholds. The lower limit, the IHS criteria, may
give an overestimation, and the upper threshold,
the stringent criteria, is probably an underestimation.
With these stringent criteria, the existence of med-
ication overuse headache is evident. With the IHS
criteria there is either overuse or a high risk of
overuse.
The results are in agreement with a smaller popula-
tion-based study in Denmark. Here, 5% of sumatriptan
users used >30 DDDs per month and were responsible
for 38% of the total sumatriptan consumption and
costs (26). In two French studies, 25–30% of triptan
users were overusers (27) and 12% became overusers
(defined as 180 DDDs/yr) within one year from start-
ing using triptans (28). In an Italian study a much lower
rate of overuse was found (3.2%), but this is probably
due to a low overall use of triptans in this country (29).
One might argue that the prevalence of triptan over-
use was overestimated given the nature of sickness
fund-based databases. Patients included in such data-
bases generally tend to come from relatively lower
socio-economic classes, compared with patients with
private health insurance. Low educational level is
known to be associated with a higher risk of medication
overuse (12,30).
Given the nature of our sickness-fund-based data-
base, our population had a relatively lower socio-eco-
nomic status than the population as a whole. However,
our population represents 65% of the Dutch popula-
tion in 2005 and other studies in this database revealed
that data from these patients are similar to those in the
general population (31,32). We also compared our data
with those of a smaller database of dispensed drugs in
pharmacies, including all income classes. Those data
were very similar to those in the present study. In par-
ticular, there was no evidence for socio-economic class
major difference in use of triptans.
In our analysis we calculated the average triptan
consumption in a timeframe of 12 months, using the
criteria based on a 3-month period. In this way we were
able to provide more stable and reliable estimates than
for shorter periods, given that use and overuse of acute
anti-migraine medication are known to fluctuate sub-
stantially (12). Indeed, we found 9,120 IHS overusers
(30 DDDs or more) in the first trimester of the year,
10,287 in the second trimester, 10,128 in the third and
11,088 in the final trimester; the average was 10,156
overusers. Of all overusers in the first quarter, only
63–65% were also overusers in at least one of the sub-
sequent three trimesters.
The most striking finding of our study was that level
of overuse differed among the triptans. In particular,
use of frovatriptan, rizatriptan, and to a lesser degree
naratriptan, was associated with remarkably lower pro-
portions of overusers compared with the reference
agent sumatriptan and the other triptans. Several con-
founding factors could potentially explain this finding
and need to be discussed.
First, for practical reasons, we used the number of
DDDs to define overuse. However, triptan overuse is
in fact defined by the number of days on which at
least one dose of a triptan is taken, irrespective of the
total number of dosages per day or the milligrams
per dose. In 2001, the DDD for sumatriptan was
changed from 100mg to 50mg (http://
www.whocc.no/atcddd/) (24) Thus, one tablet of
100mg sumatriptan was suddenly equal to 2DDD.
As a result, patients using 61–107 tablets of 100mg
per year were assigned as ‘IHS overusers’ (122–214
DDDs/yr), without necessarily fulfilling the IHS cri-
teria for triptan overuse (use of at least one dose on
120 days per year). This could have potentially
biased the results against sumatriptan in these
patients. However, the risk of incorrectly assigning
someone (this applies to each type of triptan) to
the overusers group is negligible when applying the
stringent criteria (216 DDDs/yr). The relative
degree of overuse in this group was very similar to
that when using the less stringent IHS criteria, with
the understanding that the differences with sumatrip-
tan are magnified to some extent. Use of almotriptan,
sumatriptan and zolmitriptan was in both groups
clearly associated with the highest level of overuse
and use of rizatriptan, frovatriptan, and naratriptan
was associated with the lowest level of overuse.
Furthermore, from clinical experience we know that,
for a variety of reasons, many patients divide 100mg
tablets into two of 50mg, thereby doubling the
actual number of doses used. Another reason that
the extent of any possible bias by an erroneous clas-
sification of the WHO-DDD is small is that only
27.6% of all sumatriptan is delivered by pharmacies
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as 100mg tablets. Consequently, any possible bias by
an erroneous classification of the WHO-DDD is
small in relation to the difference we found. We
are, therefore, confident that the applied approach
provides a reliable estimate of the relative levels of
overuse for the various triptans.
A second potential confounding factor is that
patients with cluster headache may sometimes use
very high quantities of subcutaneous sumatriptan to
treat their attacks, without necessarily being an overu-
ser (33,34). This could have biased the results towards
overuse of sumatriptan. However, use of the subcuta-
neous formulation of sumatriptan made up for only
8.8% of the total use of sumatriptan in the IHS overuse
group and for only 5.7% in the stringent overuse
group. This is less than in the non-overuse group
(10.5%), making a major impact of overuse of subcu-
taneous sumatriptan unlikely. In other countries than
the Netherlands, cluster headache patients are some-
times treated with high dosages of oral sumatriptan
because of cost considerations. All triptans are carefully
reimbursed in the Netherlands, so this is unlikely in
present study.
A third potential bias that we need to discuss is
the difference in duration of availability of the vari-
ous triptans (Table 1). This might have led to pref-
erential use of the agents available earlier by the most
disabled patients, who are likely to have a higher
level of overuse. Sumatriptan was the first available
triptan (1991), but because of complicated reimburse-
ment issues in the Netherlands, the oral formulation
became fully reimbursed only in 1996. Sales for
sumatriptan really started only then. Overuse before
that time was very rare in the Netherlands (35). The
other triptans were always fully reimbursed from the
date of introduction. After adjusting for duration of
availability of the drug (for sumatriptan from year of
full reimbursement), the rate differences compared
with sumatriptan disappeared for zolmitriptan, ele-
triptan, and almotriptan, but clearly remained for
frovatriptan and rizatriptan, and to a lesser extent
for naratriptan (Table 5).
Given the nature of the present observational study,
we can only speculate as to (i) what the possible reasons
and mechanisms are for the observed reduced levels of
overuse; (ii) whether these represent a true clinical ben-
efit; and (iii) whether this benefit applies to all three
triptans. Frovatriptan was introduced 10 years after
sumatriptan and consequently the absolute numbers
for users (N¼ 957) and overusers (N¼ 17) in 2005
were very small compared with those for sumatriptan
(N¼ 41,352 users and N¼ 5,554 overusers) and most
other triptans; the user numbers for naratriptan were
also very small. Furthermore, frovatriptan and nara-
triptan were marketed as ‘gentle’ triptans, with fewer
adverse events and a slower onset of action, best suited
for milder migraine attacks (16). Combined with their
significantly lower 2-hr and 24-hr efficacy rates (16),
this might well have led to a preferential use of frova-
triptan and naratriptan by patients with milder
migraines, which are known to be associated with a
lower level of overuse. These considerations do not
seem to apply to rizatriptan, whose user numbers
were very high (N¼ 25,796 users and N¼ 1,026 overu-
sers) and whose 2-hr and 24-hr efficacy rates are among
the highest of all triptans (16).
One can ask whether the package size of the triptans
can explain the differences. However, triptans are used
in such large quantities that each prescription usually
involves multiple packages. The package size of the
various triptans varies. Nevertheless, we found no cor-
relation between the size of the package and the asso-
ciation with overuse for the various triptans (data not
shown).
Whether the observed differences also reflect a true
clinical benefit can only be tested in prospective ran-
domized clinical trials.
Overusers accounted for almost half of the total
costs of triptans. These costs could be significantly
reduced if physicians monitored prescriptions better
and considered prophylactic treatment earlier in
case of increasing headache frequency to prevent
overuse. Once overuse is established, withdrawal of
overused medication is the most appropriate
therapy (36).
To our knowledge, this is the first extensive study
reporting the prevalence of overuse of all currently
available triptans in the general population. Although
the overall prevalence of overuse was low, overuse
accounted for a large health burden and a substantial
proportion of total costs of migraine therapy. The level
of overuse differs per triptan. Whether this reflects a
true clinical benefit needs to be investigated in prospec-
tive studies.
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